Data to be Presented at AACR Congress 2024
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your HCM notes
Hong Kong, Shanghai & Florham Park, NJ - Friday, April 5, 2024: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research ("AACR") Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California.
Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia. Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models. Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib synergistically improved the anti-tumor effect against MLL-rearranged leukemias both in vitro and in vivo. The investigational drug candidate displayed favorable pharmacokinetic profiles, high selectivity and low risk of cardiac toxicity. A Phase I study of HMPL-506 is planned for the second half of 2024.
Initial preclinical data will also be presented for HMPL-A067 (HMA800067), a novel CD38-targeting antibody-drug conjugate (ADC) in which daratumumab was conjugated with cytotoxic payload Monomethyl auristatin E (MMAE) via a novel linker. It demonstrated significant superior anti-tumor activity to daratumumab, including in several B-cell malignancies models with resistance to daratumumab treatment.
Other presentations include preclinical data on the ERK 1/2 inhibitor, HMPL-295; early clinical data on the Syk inhibitor, sovleplenib, in lymphoma patients; additional clinical data from global studies of VEGFR inhibitor, fruquintinib, and MET inhibitor, savolitinib; and several investigator-initiated studies of fruquintinib and VEGFR/CSF-1R/FGFR inhibitor, surufatinib.
Details of the presentations are as follows:
| Abstract title | Presenter / Lead author | Presentation details |
| SPONSORED STUDIES | ||
| HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of MLL-rearranged and NPM1 mutant acute leukemia in preclinical models | Min Cheng, HUTCHMED, Shanghai, China | #2113 Poster Session (PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response) Monday, April 8 , 202 4 |
| HMPL-A067 (HMA800067), a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models | Yan Xu , HUTCHMED, Shanghai, China | #1890 Poster Session (PO.ET01.02 - Antibody-Drug Conjugates and Bispectific Antibodies) Monday, April 8 , 202 4 |
| Preclinical characterization of HMPL-295, a potent and selective ERK1/2 inhibitor | Jia Hu , HUTCHMED, Shanghai, China | #1661 Poster Session (PO.MCB03.01 - Cell Signaling Components as Therapeutic Targets) Monday, April 8 , 202 4 |
| Targeting YAP1/TEAD signaling re-sensitizes MAPK/ERK pathway inhibitors in KRAS-driven cancer cells | Xianwen Yang , HUTCHMED, Shanghai, China | #1931 Poster Session (PO.ET03.04 - Drug Resistance 2: Ras GTPase) Monday, April 8 , 202 4 |
| Safety and Efficacy of Sovleplenib (HMPL-523), a Syk Inhibitor, in Patients with Relapsed or Refractory Lymphoma | Paolo Strati, The University of Texas MD Anderson Cancer Center, USA | #CT144 Poster Session (PO.CT01.03 - Phase 0 and Phase I Clinical Trials) Monday, April 8 , 202 4 |
| Early carcinoembryonic antigen (CEA) dynamics to predict the efficacy of fruquintinib (F) + best supportive care (BSC) in patients with metastatic colorectal cancer (mCRC) enrolled in FRESCO-2 | Stefano Lonardi , Veneto Institute of Oncology IOV-IRCCS Padua, Italy | #6408 Poster Session (PO.CL01.10 - Predictive Biomarkers 5) Tuesday , April 9 , 202 4 |
| Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi | James Chih-Hsin Yang, National Taiwan University Hospital and National Taiwan University Cancer Centre, Taipei, Taiwan | #CT251 Poster Session (PO.CL01.10 - Predictive Biomarkers 5) Tuesday , April 9 , 202 4 |
| INVESTIGATOR-INITIATED STUDIES | ||
| Enhanced anticancer efficacy via ROS-dependent ferroptosis: synergy between surufatinib and cisplatin in small cell lung cancer | Xiaolin Li , First Affiliated Hospital of Nanjing Medical University, Nanjing, China | #2122 Poster Session (PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response) Monday, April 8 , 202 4 |
| Efficacy and underlying mechanisms of surufatinib in non-small cell lung cancer treatment | Yanfang Zheng, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China | #2126 Poster Session (PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response) Monday, April 8 , 202 4 |
| Enhancing Radiosensitivity in Biliary Tract Cancer: The Dual Role of Surufatinib in Tumor Suppression and Macrophage Reprogramming | Hong Ma , Wuhan Union Hospital, Wuhan, China | #2127 Poster Session (PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response) Monday, April 8 , 202 4 |
| Surufatinib treatment in pancreatic cancer: unveiling the role of GPR34 in TAMs and enhancing immunotherapy efficacy | Jihui Hao / Song Gao, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China | #2128 Poster Session (PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response) Monday, April 8 , 202 4 |
| Efficacy and Underlying Mechanisms of Surufatinib Combined with PD-1 Monoclonal Antibody and Chemotherapy in Pancreatic Cancer | Guanghai Dai / Ru Jia, Chinese PLA General Hospital (CPLAGH), Beijing, China | #2129 Poster Session (PO.ET07.02 - Pharmacodynamic Biomarkers of Drug Response) Monday, April 8 , 202 4 |
| Optimizing the treatment schedule of radiotherapy combined with VEGFR-TKIs and PD-(L) 1 inhibitors in metastatic colorectal cancer | Tao Zhang / Zhenyu Lin, Cancer Center, Union Hospital Tongji Medical College , Huazhong University of Science and Technology, Wuhan, China | #3827 Poster Session (PO.CL10.04 - Outcome Investigation with Real World Data) Monday, April 8 , 202 4 |
| Clinical and epidemiological profile of neuroendocrine differentiation- A hospital-based retrospective study | Susheng Shi / Yaru Wen , Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China | #4630 Poster Session (PO.ET06.04 - Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes) Tuesday, April 9, 2024 |
| Epidemiological characteristics and treatment strategies of gastric cancer with neuroendocrine differentiation (NED) | Jun Zhang , The First Affiliated Hospital of Chongqing Medical University, Chongqing, China | #4864 Poster Session (PO.PS01.08 - Descriptive Epidemiology and Statistical and Epidemiological Methodology) Tuesday, April 9, 2024 |
| Initial efficacy of surufatinib plus sintilimab and IBI310 for patients with high-grade advanced-neuroendocrine neoplasm: A multicenter, single arm phase 2 study | Lin Shen / Ming Lu, Peking University Cancer Hospital and Institute, Beijing, China | #CT266 Poster Session (PO.CT02.02 - Phase II Clinical Trials 2) Tuesday, April 9, 2024 |
Medical Information
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.